[go: up one dir, main page]

AU2020903781A0 - Pharmaceutical formulations - Google Patents

Pharmaceutical formulations

Info

Publication number
AU2020903781A0
AU2020903781A0 AU2020903781A AU2020903781A AU2020903781A0 AU 2020903781 A0 AU2020903781 A0 AU 2020903781A0 AU 2020903781 A AU2020903781 A AU 2020903781A AU 2020903781 A AU2020903781 A AU 2020903781A AU 2020903781 A0 AU2020903781 A0 AU 2020903781A0
Authority
AU
Australia
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020903781A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avecho Biotechnology Ltd
Original Assignee
Avecho Biotechnology Ltd
Filing date
Publication date
Application filed by Avecho Biotechnology Ltd filed Critical Avecho Biotechnology Ltd
Publication of AU2020903781A0 publication Critical patent/AU2020903781A0/en
Priority to EP21881370.7A priority Critical patent/EP4228613A4/en
Priority to US18/249,647 priority patent/US20230381208A1/en
Priority to IL302169A priority patent/IL302169A/en
Priority to AU2021366254A priority patent/AU2021366254A1/en
Priority to PCT/AU2021/051212 priority patent/WO2022082257A1/en
Priority to CA3195938A priority patent/CA3195938A1/en
Abandoned legal-status Critical Current

Links

AU2020903781A 2020-10-19 2020-10-19 Pharmaceutical formulations Abandoned AU2020903781A0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP21881370.7A EP4228613A4 (en) 2020-10-19 2021-10-18 ORAL CANNABINOID FORMULATION COMPRISING MEDIUM CHAIN TRIGLYCERIDES AND TOCOPHERYL PHOSPHATES
US18/249,647 US20230381208A1 (en) 2020-10-19 2021-10-18 Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
IL302169A IL302169A (en) 2020-10-19 2021-10-18 Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
AU2021366254A AU2021366254A1 (en) 2020-10-19 2021-10-18 Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
PCT/AU2021/051212 WO2022082257A1 (en) 2020-10-19 2021-10-18 Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates
CA3195938A CA3195938A1 (en) 2020-10-19 2021-10-18 Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates

Publications (1)

Publication Number Publication Date
AU2020903781A0 true AU2020903781A0 (en) 2020-11-12

Family

ID=

Similar Documents

Publication Publication Date Title
EP4216937A4 (en) Extended release pharmaceutical formulation
EP4188329A4 (en) Pharmaceutical formulations comprising tadalafil
EP4190310A4 (en) Stable pharmaceutical preparation
GB202005282D0 (en) Pharmaceutical Formulations
EP4230210A4 (en) Stable pharmaceutical composition
EP4205765A4 (en) Stable pharmaceutical preparation
EP4326265A4 (en) Pharmaceutical hydronidone formulations for diseases
HK40100860A (en) Pharmaceutical formulations
HK40091202A (en) Pharmaceutical formulations
HK40089663A (en) Pharmaceutical formulations
HK40085410A (en) Pharmaceutical formulations
HK40080656A (en) Pharmaceutical formulations
AU2020903780A0 (en) Pharmaceutical formulations
AU2020903781A0 (en) Pharmaceutical formulations
AU2024275492A1 (en) Pharmaceutical formulations
HK40103575A (en) Pharmaceutical formulation
HK40097541A (en) Pharmaceutical formulation
HK40090037A (en) Pharmaceutical formulation
HK40090038A (en) Pharmaceutical formulation
HK40106463A (en) Pharmaceutical composition comprising p-boronophenylalanine
HK40105586A (en) Pharmaceutical composition comprising enavogliflozin
HK40065721A (en) Pharmaceutical formulations
HK40109650A (en) Formulations
HK40109619A (en) Formulations
CA3266275A1 (en) Pharmaceutical formulation